@article{e8abbeaa5a504611b4dbe8bfcb083af0,
title = "Must beg to differ",
abstract = "The authors provide a significant interpretation of the National Eye Institute-sponsored Multicenter Uveitis Steroid Treatment study, in which patients with severe, non-infectious intermediate, posterior, or panuveitis were randomly assigned to receive local treatment using the sutured intravitreal fluocinolone acetonide implant or systemic treatment consisting of oral steroids and conventional steroid-sparing immunosuppression, with a primary outcome of visual acuity at 2 years of follow-up. The authors also present evidence-based guidance for the treatment of noninfectious posterior segment involving uveitis.",
author = "Thomas Albini and Callaway, {Natalia F.} and Jaffe, {Glenn J.} and William Feuer and Janet Davis and Debra Goldstein and Careen Lowder and Phoebe Lin and Quan Nguyen and Sunil Srivastava and David Callanan and Anat Galor and Raquel Goldhardt and Harry Flynn",
note = "Funding Information: Originally submitted July 8, 2018. Revision received March 27, 2019. Accepted for publication March 27, 2019. Supported in part by an unrestricted grant to the Bascom Palmer Eye Institute/Department of Ophthalmology University of Miami from Research to Prevent Blindness, New York, and by grants from the National Institutes of Health (NIH) (Center Core grant, P30EY014801, P30EY001319, and R01EY026174), the Department of Defense (W81XWH-09-1-0675), the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Clinical Sciences Research EPID-006-15S (AG), and the Klorfine Foundation (TA). Dr. Albini has received personal fees from Bausch + Lomb and EyePoint outside the submitted work. Dr. Jaffe has received personal fees from AbbVie outside the submitted work. Dr. Feuer received a grant from the NIH (Core Center Grant P30-EY014801) and an unrestricted grant from Research to Prevent Blindness during the conduct of this study. Dr. Davis is a consultant for AbbVie. Dr. Lin is on the advisory board for Mallinckrodt and Clearside outside the submitted work. Dr. Nguyen has received grants from and is on the scientific advisory board for Bausch + Lomb outside the submitted work. Dr. Srivastava has received grants and personal fees from Bausch + Lomb, Santen, Psivida, Allergan, and Novartis, and personal fees from Regeneron, Zeiss, and Optos outside the submitted work. Dr. Callanan is a consultant for AbbVie, Allergan, EyePoint, Eyevensys, Graybug, Regeneron, and Santen. The remaining authors report no relevant financial disclosures. The authors would like to acknowledge John Kempen, MD, MPH, PhD, MHS, international vice-chair of the Multicenter Uveitis Steroid Treatment (MUST) trial, for his critical review of this manuscript. Address correspondence to Thomas Albini, MD, Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine, 900 NW 17th Street, Miami, FL 33136; email: talbini@med.miami.edu. doi: 10.3928/23258160-20190503-01 Publisher Copyright: {\textcopyright} 2019 Slack Incorporated. All rights reserved.",
year = "2019",
doi = "10.3928/23258160-20190503-01",
language = "English (US)",
volume = "50",
pages = "266--268",
journal = "Ophthalmic Surgery Lasers and Imaging Retina",
issn = "2325-8160",
publisher = "Slack Incorporated",
number = "5",
}